Jonathan A. Colasanti, MD, MSPH
Dr. Jonathan Colasanti, MD, MSPH, is an Assistant Professor of Medicine (Infectious Diseases) and Global Health (Rollins School of Public Health) at Emory University in Atlanta, Georgia. He completed medical school and a Master’s in Public Health at the University of Miami. He completed his Internal Medicine and Global Health Residency at the University of Miami and his Infectious Diseases fellowship at Emory University.
Colasanti developed a passion for HIV in high school and has dedicated himself to the field ever since. He has experience treating PLHIV in Miami, Atlanta, Peru, Nicaragua and Ethiopia, giving him a global perspective of HIV treatment and care. His clinical and research interests focus on the delivery of HIV care to vulnerable populations, across the spectrum of the HIV care continuum. In his research, he seeks to bridge the implementation gap in order to improve the delivery of HIV care, by addressing socio-behavioral, biomedical, and systems-level barriers. In addition to his Atlanta-based work, he serves on the U.S. advisory board for a Nicaraguan NGO that strives to improve the delivery of primary health care in Nicaragua through a community health worker model.
Board Certifications
American Board of Internal Medicine
Affiliations
Emory
Education & Training
- Medical School: University of Miami Miller School of Medicine
- Internship: University of Miami - Jackson Health System
- Residency: University of Miami/Jackson Memorial Hospital
Fellowships
Emory University School of Medicine
Locations and Directions
Ponce De Leon Center
Monday – Friday: 8 a.m. – 5 p.m.
Extended hours on Thursday
Publications
- What Do People with HIV Want to Know About Long-Acting Injectable Cabotegravir/Rilpivirine?
Dawdani A, Dance KV, McNulty MC, Erguera XA, Flores R, Smith MB, Tsuzuki MD, Pareek P, Balter L, Montgomery ET, Johnson MO, Sauceda J, Hickey MD, Collins LF, Colasanti JA, Koester KA, Christopoulos KA
AIDS and behavior. 2026;
PMID: 42850545 - Satisfaction and Treatment Burden Among Early Adopters of Long-Acting Injectable Cabotegravir-Rilpivirine With and Without Viremia in Three US Ryan White Clinics.
Christopoulos KA, Beckert A, McCracken C, Dance K, Plotkin S, Collins LF, McNulty MC, Hickey MD, Johnson MO, Mody A, Erguera XA, Koester KA, Liegeon G, Salazar J, Gutierrez J, Grochowski J, Dilworth SE, Neilands TB, Montgomery ET, Colasanti JA
Open forum infectious diseases. 2026;13(9):ofag559.
PMID: 42774744 - Retention in care: is it still a clinically useful indicator for monitoring long-term engagement in HIV care in the treat-all era?
Lujintanon S, Rebeiro PF, Althoff KN, Jones JL, Zalla LC, Haw NJL, Hogan BC, Hackstadt AJ, Yazdani E, Horberg MA, Moore RD, Edwards JK, Napravnik S, Colasanti JA, Marconi VC, Lam JO, Park LS, Gebo KA, Lesko CR,
AIDS (London, England). 2026;
PMID: 42758482 - Evolution of ART Medication Adherence Support and Monitoring Across IeDEA Sites: Results From Three Waves of Consortium-Wide Site Assessment Surveys, 2017, 2020 and 2023.
Brazier E, Odhiambo F, Edwards JK, Zalla L, Kasozi C, Messou E, Schreuder C, Chaiwarith R, Rodríguez MF, Ayakaka I, Zannou M, Freeman A, Ebasone PV, Muktiarti D, Semeere A, Khol V, Mensah E, Cesar C, Tanser F, Sang E, Do CD, Poda A, Niyongabo A, Vega YC, Colasanti JA, Rafael I, Lelo P, Murenzi G, Nash D,
Journal of the International AIDS Society. 2026;29(9):e70197.
PMID: 42693737 - Accelerating Low-Barrier Use of Long-Acting Antiretroviral Therapy to Maximize Impact in People with HIV and Viremia or Adherence Challenges.
Collins LF, Chmura C, Philbin MM, Colasanti JA
Current HIV/AIDS reports. 2026;
PMID: 42525311 - Virologic Outcomes After LA ART Initiation with and without Viremia in Two Large U.S. Clinic Cohorts.
Spinelli M, Heise MJ, Glidden DV, Grochowski J, Oskarsson J, Niles-Carnes L, Ochieng E, Lora M, Aldredge A, Gistand N, Cox C, Colasanti JA, Gandhi M, Collins LF
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2026;
PMID: 42372087 - Optimizing the patient journey: Insights from early implementation of long-acting cabotegravir and rilpivirine in four urban Ryan White-funded clinics in the United States.
Erguera XA, Smith MB, Pareek P, Dawdani A, Dance KV, Walker RS, Grochowski J, Oskarsson J, Hickey MD, Johnson MO, Sauceda J, Gutierrez JI, Montgomery ET, Colasanti JA, Collins LF, McNulty MC, Koester KA, Christopoulos KA
Journal of the International AIDS Society. 2026;29(2):e70082.
PMID: 41681062 - Frequent Missed Opportunities for Earlier HIV Diagnosis in a Routine Opt-out Testing Environment in Atlanta.
Gruber SF, Schwinne M, Iytha R, Hollenberg EJ, Robichaux C, Cantos VD, Colasanti JA, Yaffee AQ, Turbow S, Leue E, Camacho-González A, Wang YF, Lora MH
Open forum infectious diseases. 2025;12(8):ofaf423.
PMID: 40874191 - Long-Acting Cabotegravir/Rilpivirine, Lenacapavir, and Ibalizumab Use Among Persons With HIV-1 Viremia at a Ryan White-Funded Clinic in the Urban US South.
Colasanti JA, Aldredge A, Niles-Carnes LV, Ochieng E, Pareek P, Robinson V, Anderson E, Castaneda M, Spralling H, Smith BL, Sumitani J, Paul Leue E, Moran CA, Lora M, Armstrong WS, Collins LF
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2026;82(4):564-574.
PMID: 40747944 - Comparing Interest in Thigh Administration of Long-acting Cabotegravir/Rilpivirine Among Hypothetical Users, Early Adopters, and Trial Participants With Experience.
Collins LF, Christopoulos KA, McNulty MC, Colasanti JA
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2025;81(5):e477-e479.
PMID: 40560533
PLANNING
PREPARING FOR YOUR VISIT
Whether you’re a patient or you’re visiting one, a little planning beforehand can make your visit to Grady easier and more comfortable. Here, you’ll find everything you need to prepare for your visit, including an appointment checklist, admissions information, dining options, and much more.